title: Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
authors.affiliation: Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
authors.forename: Walla A
authors.initials: WA
authors.lastname: Alfaraj
authors.affiliation: Department of Neurology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors.forename: David
authors.initials: D
authors.lastname: Cachia
authors.affiliation: Department of Neurology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors.forename: Sudhakar
authors.initials: S
authors.lastname: Tummala
authors.affiliation: Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
authors.forename: Sheeba K
authors.initials: SK
authors.lastname: Thomas
authors.affiliation: Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA. EEManasanch@mdanderson.org.
authors.forename: Elisabet E
authors.initials: EE
authors.lastname: Manasanch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D009842:Oligopeptides; D000069283:Rituximab; C524865:carfilzomib; D003907:Dexamethasone